Merck KgaA Files European Marketing Application for Multiple Sclerosis Drug

Merck KGaA has filed a marketing authorization application with the European Medicines Agency for cladribine tablets, the company's proprietary investigational oral formulation of cladribine, as a therapy for patients with relapsing-remitting multiple sclerosis.

According to Merck, cladribine tablets could become the first orally administered disease-modifying therapy available for patients with multiple sclerosis (MS), as all disease-modifying therapies currently approved for the treatment of MS are injectable.

The marketing authorization application submission is supported by results from the Clarity study, a two-year, randomized, double-blind, placebo-controlled Phase III trial of cladribine tablets in patients with relapsing-remitting MS.

Merck is currently submitting new drug applications for cladribine tablets in several other countries, including the US in the current quarter.



Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying